(Q48457699)

11 February 2018

http://europepmc.org/abstract/MED/25392330

title

Brain atrophy in natalizumab-treated patients: A 3-year follow-up (English)

1 reference

11 February 2018

http://europepmc.org/abstract/MED/25392330

author

Mar Tintoré

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25392330%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Jaume Sastre Garriga

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25392330%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Carmen Tur

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25392330%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Deborah Pareto

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25392330%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Angela Vidal-Jordana

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25392330%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Jordi Rio

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25392330%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Xavier Montalban

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25392330%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

C Auger

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25392330%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

E Huerga

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25392330%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

A Rovira

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25392330%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

publication date

12 November 2014

1 reference

11 February 2018

http://europepmc.org/abstract/MED/25392330

published in

Multiple Sclerosis Journal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25392330%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25392330%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25392330%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

749-756

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25392330%20AND%20SRC:MED&resulttype=core&format=json

Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences

8 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

The measurement and clinical relevance of brain atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Differential aging of the brain: patterns, cognitive correlates and modifiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Gray matter atrophy in multiple sclerosis: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Progressive cerebral atrophy in multiple sclerosis. A serial MRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Normalized accurate measurement of longitudinal brain change.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

The relationship between inflammatory activity and brain atrophy in natalizumab treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis--a prospective, non-randomized pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Eight-year follow-up study of brain atrophy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

Clinical impact of early brain atrophy in clinically isolated syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514556300

21 January 2018

Identifiers

DOI

10.1177/1352458514556300

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25392330%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

1 reference